Skip to main content

Fragment Screen

  • Reference work entry
Encyclopedia of Biophysics

Synonyms

NMR; NMR ligand affinity screen

Definition

The development of the SAR by NMR technique in 1996 by Stephen Fesik at Abbot Laboratories resulted in a tremendous expansion in NMR ligand affinity screens throughout the pharmaceutical industry (Shuker et al. 1996). One important enhancement has been the design of the chemical library used in these NMR screens. Instead of a library of random compounds, screening libraries were constructed to contain fragments of known drugs. This was first demonstrated with the SHAPES library designed by Jonathan Moore at Vertex Pharmaceuticals (Fejzo et al. 1999). Fragment-based screens utilize a structurally diverse chemical library of low molecular-weight compounds (≤200–300 Da) that correspond to fragments of known drugs or have drug-like characteristics by adhering to Lipinski’s rule of five and exhibiting high aqueous solubility (Lipinski et al. 2001, Lipinski 2004). A fragment library is typically small (<105compounds) making it amenable to...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 999.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,099.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Reference

  • Baurin N, Aboul-Ela F, Barril X, Davis B, Drysdale M, Dymock B, Finch H, Fromont C, Richardson C, Simmonite H, Hubbard RE. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci. 2004;44(6):2157–66.

    CAS  PubMed  Google Scholar 

  • Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay, Murcko MA, et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol. 1999;6(10):755–69.

    CAS  PubMed  Google Scholar 

  • Hajduk PJ, Galloway WRJD, Spring DR. Drug discovery: a question of library design. Nature. 2011;470:42–3.

    CAS  PubMed  Google Scholar 

  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.

    CAS  PubMed  Google Scholar 

  • Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technol. 2004;1:337–41.

    CAS  Google Scholar 

  • Powers R. Advances in nuclear magnetic resonance for drug discovery. Expert Opin Drug Discov. 2009;4(10):1077–98.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Reynolds CH, Bembenek SD, Tounge BA. The role of molecular size in ligand efficiency. Bioorg Med Chem Lett. 2007;17(15):4258–61.

    CAS  PubMed  Google Scholar 

  • Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274(5292):1531–4.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert Powers .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 European Biophysical Societies' Association (EBSA)

About this entry

Cite this entry

Powers, R., Copeland, J.C. (2013). Fragment Screen. In: Roberts, G.C.K. (eds) Encyclopedia of Biophysics. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16712-6_327

Download citation

Publish with us

Policies and ethics